Efficacy and Neural Mechanisms of Transcranial Direct Current Stimulation Targeting the Supplementary Motor Area for the Treatment of Subacute Post-stroke Aphasia
2026年7月15日 更新者:Panpan Hu, MD、The First Affiliated Hospital of Anhui Medical University
Study on the Efficacy and Neural Mechanisms of Transcranial Direct Current Stimulation Targeting the Supplementary Motor Area for the Treatment of Subacute Post-stroke Aphasia
This study aims to investigate the efficacy of transcranial direct current stimulation (tDCS) in patients with post-stroke aphasia (PSA) and to explore its potential neural mechanisms.
The study will recruit PSA patients and provide them with 14 tDCS sessions over 7 days, along with speech therapy.
Language Behavior Scale scores and resting-state functional MRI scans will be collected before and after the intervention.
In addition, a retrospective comparison will be conducted of language function and resting-state fMRI changes in a group of PSA patients who received only speech therapy; these patients did not undergo any physical intervention but received only speech therapy.
Changes in Language Behavior Scale scores and functional connectivity (FC) before and after treatment in the speech therapy-only group will be analyzed and compared with those in the tDCS intervention group.
研究概览
研究类型
介入性
注册 (估计的)
40
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Jian Guan
- 电话号码:+86-19810696998
- 邮箱:1003935828@qq.com
学习地点
-
-
Anhui
-
Hefei、Anhui、中国
- 招聘中
- transcranial direct current stimulation (tDCS)
-
接触:
- Jian Guan
- 电话号码:+86-19810696998
- 邮箱:1003935828@qq.com
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- Patients must be between 18 and 80 years of age
- First stroke in the left hemisphere
- Stroke onset within the past 12 weeks
- Native Chinese speakers who were able to communicate normally prior to onset
- Diagnosed with aphasia using the ABC scale
- Right-handed
- Informed consent obtained from the patient and family members
Exclusion Criteria:
- Time since stroke onset exceeds 12 weeks
- History of psychiatric or neurological disorders
- History of surgery for severe head trauma, brain tumors, or brain abscesses
- Severe articulation disorders
- Claustrophobia or implants incompatible with MRI
- Inability to cooperate with language scale testing or fMRI scanning
- History of previous stroke
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:tDCS group
PSA patients enrolled in the tDCS group received tDCS treatment twice daily for 7 consecutive days, along with 7 days of speech-language therapy.
The current intensity was 2 mA, and each treatment session lasted 20 minutes.
|
As a non-invasive brain stimulation technique, tDCS offers advantages such as convenience, safety, and low cost.
Its mechanism of action involves regulating neuronal activity in the brain by applying a weak direct current to the scalp.
|
|
无干预:The speech-language therapy group
The speech-language therapy group received only 7 days of speech-language therapy.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Aphasia quotient (AQ)
大体时间:Baseline, immediately after all interventions have ended
|
The Aphasia Battery of Chinese (ABC) is a standardized Chinese adaptation of the Western Aphasia Battery (WAB).
The Aphasia Quotient (AQ) is a composite score that reflects the overall severity of language impairment.
The AQ score ranges from a minimum of 0 to a maximum of 100.
Higher scores indicate better language function (i.e., less severe impairment).
|
Baseline, immediately after all interventions have ended
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
rs-fMRI
大体时间:Baseline, immediately after all interventions have ended
|
Baseline, immediately after all interventions have ended
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2025年7月30日
初级完成 (估计的)
2027年1月1日
研究完成 (估计的)
2027年1月31日
研究注册日期
首次提交
2026年7月8日
首先提交符合 QC 标准的
2026年7月11日
首次发布 (实际的)
2026年7月14日
研究记录更新
最后更新发布 (实际的)
2026年7月17日
上次提交的符合 QC 标准的更新
2026年7月15日
最后验证
2026年7月1日
更多信息
与本研究相关的术语
其他研究编号
- AHMU-tDCS-PSA
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
IPD 计划说明
Individual participant data will not be shared with other researchers due to patient privacy protection and the limitations of the informed consent form.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.